Changes of in vitro potency of anticoagulant drugs are similar between patients with cirrhosis due to alcohol or non-alcoholic fatty liver disease
- 14 December 2016
- journal article
- Published by Elsevier BV in Thrombosis Research
- Vol. 150, 41-43
- https://doi.org/10.1016/j.thromres.2016.12.008
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Preserved hemostatic status in patients with non-alcoholic fatty liver diseaseJournal of Hepatology, 2016
- Direct Oral Anticoagulants in Cirrhosis Patients Pose Similar Risks of Bleeding When Compared to Traditional AnticoagulationDigestive Diseases and Sciences, 2016
- Vascular Disease in Patients with Nonalcoholic Fatty Liver DiseaseSeminars in Thrombosis and Hemostasis, 2015
- Decreased in vitro anticoagulant potency of Rivaroxaban and Apixaban in plasma from patients with cirrhosisJournal of Hepatology, 2014
- Differential In Vitro Inhibition of Thrombin Generation by Anticoagulant Drugs in Plasma from Patients with CirrhosisPLOS ONE, 2014
- Increased anticoagulant response to low‐molecular‐weight heparin in plasma from patients with advanced cirrhosisJournal of Thrombosis and Haemostasis, 2012
- Rebalanced hemostasis in patients with liver disease: evidence and clinical consequencesBlood, 2010
- Safety and Efficacy of Anticoagulation Therapy With Low Molecular Weight Heparin for Portal Vein Thrombosis in Patients With Liver CirrhosisJournal of Clinical Gastroenterology, 2010
- Nonalcoholic Fatty Liver Disease as a Contributor to Hypercoagulation and Thrombophilia in the Metabolic SyndromeSeminars in Thrombosis and Hemostasis, 2009
- Calibrated Automated Thrombin Generation Measurement in Clotting PlasmaPathophysiology of Haemostasis and Thrombosis, 2003